A bill to require the Administrator of the Centers for Medicare & Medicaid Services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials.
About This Bill
Committee
Latest Action · August 6, 2026
Read twice and referred to the Committee on Finance.
The American Pharmaceutical Security Act directs the Centers for Medicare & Medicaid Services to study how the government can use its power to set drug prices and coverage policies to strengthen domestic production of active pharmaceutical ingredients and key materials used in drug manufacturing. The bill requires a report to Congress within one year that examines ways to reduce U.S. reliance on foreign adversaries for these critical pharmaceutical supplies and protect American manufacturers from unfair pricing practices. The report should recommend potential price floor policies to support domestic production and suggest prioritizing domestically made ingredients over foreign ones when available. The legislation also requires the Administrator to identify any data gaps about where pharmaceutical ingredients come from and who owns them. This bill affects drug manufacturers, healthcare payers, and ultimately consumers by potentially increasing support for domestic pharmaceutical production infrastructure.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.